Usefulness and Safety of Remote Continuous Glucose Monitoring for a Severe COVID-19 Patient with Diabetes

Diabetes Technol Ther. 2021 Jan;23(1):78-80. doi: 10.1089/dia.2020.0237. Epub 2020 Jul 15.

Abstract

Diabetes is associated with mortality and severity of coronavirus disease (COVID-19). Protecting against infection in health care workers at high risk of COVID-19 is critical. This report investigates the usefulness and safety of remote continuous glucose monitoring (CGM) in a patient with diabetes and severe interstitial pneumonia caused by the coronavirus disease. The Dexcom G4 Platinum CGM system® was used to monitor blood glucose (BG) levels from outside the patient's isolation room. Continuous insulin infusion rates and boluses were determined based on the patient's BG levels. Real-time CGM made it possible to track BG trends and prevent dramatic variations in BG, although the rate of insulin infusion changed dynamic. Furthermore, the need for health care workers to enter the isolation room was minimized because the Dexcom G4 Platinum CGM system can evaluate from a distance of up to 6.0 m.

Keywords: COVID-19; Diabetes; Health care workers; Remote continuous glucose monitoring; SARS-CoV-2.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Blood Glucose / analysis
  • Blood Glucose Self-Monitoring / methods*
  • COVID-19 / epidemiology*
  • COVID-19 / therapy*
  • Comorbidity
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / epidemiology*
  • Diabetes Mellitus, Type 2 / therapy*
  • Extracorporeal Membrane Oxygenation
  • Humans
  • Insulin / administration & dosage
  • Male
  • Renal Dialysis
  • SARS-CoV-2*

Substances

  • Blood Glucose
  • Insulin